Keep in mind this is not the whole thing and I could have interpreted it wrong, but this was the email I got last night its an amendment to form S-1 also I received a 10 -k
EXPLANATORY NOTE
This Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-160778) and the Registration Statement on Form S-1 (File No. 333-162361) (together, the “Registration Statement”) of ADVENTRX Pharmaceuticals, Inc. (the “Company”) is being filed pursuant to the undertakings in Item 17 of the Registration Statement to update and supplement the information contained in the Registration Statement, as originally declared effective by the Securities and Exchange Commission on October 6, 2009, to include the information contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 (the “Annual Report”) that was filed with the Securities and Exchange Commission on March 18, 2010. No changes have been made to the prospectus contained in the Registration Statement (which prospectus continues to form a part of this Registration Statement) and, accordingly, such prospectus has not been reprinted in Part I of this filing. No additional securities are being registered under this Post-Effective Amendment No. 1. All applicable registration fees were paid at the time of the original filing of the Registration Statement.
The information in this prospectus supplement is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
Prospectus Supplement No. 6
(to Prospectus dated October 6, 2009) Filed pursuant to Rule 424(b)(3)
Registration Statement Nos. 333-160778
333-162361
PRELIMINARY AND SUBJECT TO COMPLETION, DATED March 18, 2010
ADVENTRX PHARMACEUTICALS, INC.
11,283 shares of 4.25660% Series D Convertible Preferred Stock
Warrants to Purchase up to 19,800,000 shares of Common Stock
79,800,000 shares of Common Stock Underlying the Convertible Preferred Stock and the Warrants
Pursuant to the prospectus dated October 6, 2009, we offered up to $11,283,000 of our 4.25660% Series D Convertible Preferred Stock, or 11,283 shares based on a stated value of $1,000 per share, and warrants to purchase up to 19,800,000 shares of our common stock. Delivery of the convertible preferred stock and warrants was made on or about October 9, 2009. Pursuant to that prospectus, as subsequently supplemented, we are also offering 79,800,000 shares of our common stock issuable upon conversion of the convertible preferred stock and exercise of the warrants. All of the convertible preferred stock has been converted into shares of our common stock and we did not receive any proceeds upon conversion of the convertible preferred stock. The warrants, which have an exercise price of $0.1468 per share, are currently exercisable and may be exercised at any time on or before October 9, 2014.
Recent Developments
We have incorporated by reference into this prospectus supplement the Annual Report on Form 10-K of ADVENTRX Pharmaceuticals, Inc. for the fiscal year ended December 31, 2009 (the “Annual Report”). This prospectus supplement should be read in conjunction with the prospectus dated October 6, 2009, prospectus supplement No. 1 filed on November 10, 2009, prospectus supplement No. 2 filed on January 4, 2010, prospectus supplement No. 3 filed on January 4, 2010, prospectus supplement No. 4 filed on February 11, 2010, and prospectus supplement No. 5 filed on March 1, 2010 (collectively, the “Prospectus”), which is to be delivered with this prospectus supplement. This prospectus supplement updates and supplements the information in the Prospectus. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.
Investing in our securities involves a high degree of risk. Before buying any of our securities, you should read the discussion of material risks of investing in our securities in “Risk Factors” beginning on page 6 of the Prospectus and beginning on page 15 of the Annual Report.
You should rely only on the information contained in the Prospectus, any free writing prospectus prepared by us or on our behalf and this prospectus supplement. We have not authorized anyone to provide you with different or additional information. If anyone provides you with different or additional information, you should not rely on it.
Our common stock is listed on the NYSE Amex under the symbol “ANX.” The last reported sale price of our common stock on the NYSE Amex on March 17, 2010 was $0.2399 per share. We do not intend to list the convertible preferred stock or warrants on any securities exchange.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
News 
Market Data 
Discover 
AI
